Success Story: In Just 17 Days, A Chinese Senior Scientist Received O1A Approval with the help of NAILG’s teamwork and Direct Premium Service

Client’s Testimonial:

“Thank you so much, my attorney and Wegreened! I truly appreciate all your time and effort in expediting my application. I would really love to recommend you to all the people who ever need any immigrant help.”

On June 28^th, 2025, we received another O1-A (Individuals with Extraordinary Ability or Achievement) approval for a Senior Scientist in the Field of Biotherapeutics (Approval Notice).

General Field: Biotherapeutics

Position at the Time of Case Filing: Senior Scientist

Country of Origin: China

State of Residence at the Time of Filing: California

Approval Notice Date: June 28^th, 2025

Processing Time: 17 days (Premium Processing Requested)

Case Summary:

We are thrilled to share the successful outcome of an O1-A petition filed by North America Immigration Law Group (NAILG) on behalf of a talented biotherapeutics researcher specializing in the structural biology of proteins and ribonucleic acids (RNAs). Holding a Ph.D. in biochemistry and biophysics, our client is currently employed as a senior scientist in the United States and has made original contributions to the advancement of antibody discovery and high-pressure biomolecular research. This case was filed with direct premium processing and approved in just 17 days, highlighting the strength and clarity of the petition.

Revolutionizing Protein and RNA Structural Biology

Our client’s scientific journey has focused on leveraging high-pressure techniques to reveal structural dynamics in proteins and RNAs, critical molecules involved in numerous physiological processes and therapeutic targets. Her research utilizes advanced tools like high-pressure small-angle X-ray scattering (HP-SAXS) and high-resolution nuclear magnetic resonance (NMR) spectroscopy to elucidate mechanisms of protein folding and RNA conformational changes under stress conditions. These efforts have paved the way for breakthroughs in therapeutic protein design, the understanding of disease-related molecular mechanisms, and improvements in antibody screening and characterization workflows.

Recognized Contributions and Global Impact

NAILG structured the petition to highlight the major significance of our client’s research. We provided concrete evidence of her accomplishments and their broad scientific influence, including:

● 5 peer-reviewed journal articles and 10 scientific abstracts
● 36 citations by independent researchers from globally respected institutions
● At least 5 formal peer reviews for reputable journals in her field
● Research funded by premier institutions, including the National Science Foundation (NSF), National Institutes of Health (NIH), NASA, and several top European scientific agencies

Endorsements from Distinguished Experts

The petition included four compelling recommendation letters from leading scientists, including two independent advisory opinions. These letters spoke to the originality, impact, and critical importance of the client’s work in biotherapeutics. One expert noted:

“Thus, [Client’s] record of achievement amply demonstrates the indispensability of her research to the United States.”

Strategic Preparation Yields Swift O1A Approval

This robust submission resulted in an RFE-free approval just 17 days after filing under direct premium processing. We proudly celebrate this success and remain confident that our client will continue to advance the field of biotherapeutics and biomedical innovation in the United States. NAILG is honored to have supported her in achieving this important immigration milestone.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.